VanEck ETF Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Eli Lilly & CoLLY | 20.23% | $177.92M | 148,335 |
| Novartis AGNVS | 10.63% | $93.44M | 596,253 |
| Merck & Co IncMRK | 9.85% | $86.58M | 673,805 |
| Novo Nordisk A/SNVO | 5.37% | $47.19M | 984,355 |
| AbbVie IncABBV | 4.57% | $40.23M | 159,879 |
| Pfizer IncPFE | 4.51% | $39.64M | 1,646,085 |
| Bristol-Myers Squibb CoBMY | 4.47% | $39.30M | 682,122 |
| GSK PLCGSK | 4.42% | $38.85M | 741,178 |
| Johnson & JohnsonJNJ | 4.35% | $38.30M | 150,793 |
| AstraZeneca PLC | 4.33% | $38.11M | 200,966 |
| McKesson CorpMCK | 4.12% | $36.25M | 47,981 |
| Sanofi SASNY | 4.00% | $35.21M | 825,430 |
| Cencora IncCOR | 3.36% | $29.51M | 104,297 |
| Haleon PLCHLN | 3.09% | $27.18M | 2,913,351 |
| Teva Pharmaceutical Industries Ltd | 3.06% | $26.89M | 793,771 |
| Takeda Pharmaceutical Co LtdTAK | 2.87% | $25.26M | 1,575,525 |
| Zoetis IncZTS | 2.10% | $18.46M | 256,845 |
| Viatris IncVTRS | 1.10% | $9.63M | 606,435 |
| Jazz Pharmaceuticals PLC | 1.08% | $9.50M | 39,436 |
| Axsome Therapeutics IncAXSM | 0.77% | $6.75M | 27,589 |
| Corcept Therapeutics IncCORT | 0.50% | $4.43M | 50,964 |
| Elanco Animal Health IncELAN | 0.35% | $3.11M | 126,222 |
| State Street Global AdvisorsCash or money market | 0.28% | $2.43M | 2,429,156 |
| Organon & CoOGN | 0.23% | $2.01M | 148,817 |
| Bausch Health Cos IncBHC | 0.10% | $860.86K | 174,617 |
| Perrigo Co PLC | 0.06% | $528.46K | 50,862 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.